Abstract
Sexual dysfunctions caused by the use of antidepressants are relatively common. Agomelatine has demonstrated antidepressant properties in comparative studies with sertraline, fluoxetine, and venlafaxine as active controls. The aim of this study was to evaluate the effects of agomelatine on sexual response. Acutely depressed patients (n = 25) treated with agomelatine (25–50 mg/day) were evaluated over 12 weeks. Agomelatine showed a favorable response on depressive symptoms using the Montgomery-Åsberg Depression Rating Scale throughout the study. The Clinical Global Impression improvement score at the end of the study was 1.70 (SD = 0.89). The author assessed sexual response using the Arizona Sexual Experiences Scale, the International Index of Erectile Function, and a Visual Analogue Scale for desire, arousal, time, and intensity of orgasm and vaginal lubrication. Arizona Sexual Experiences Scale scores improved after 3 weeks of treatment, mainly attributable to an improvement in women rather than in men. The Visual Analogue Scale showed improvement in all stages of sexual response in women, with minimal changes in men. Clinical Satisfaction Scores at the end of the study for all patients were 7.00 (SD = 1.53). In conclusion, agomelatine appears to be a good option for the treatment of depression because it would not have adverse effects on sexual function.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
